Diverse panel of novel target binders from IONTAS / FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline
The DynaDrive portfolio offers features that support cell culture performance across scales and accommodate high-density and next-generation cell culture processes